Maphuti Lebelo

Ms. Maphuti Lebelo

University of Pretoria
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2025 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
SMS. P. Mathibela
S. P. Mathibela
KNKeith Ncube
Keith Ncube
MLMaphuti Lebelo
Maphuti Lebelo
Vanessa SteenkampVanessa Steenkamp
Vanessa Steenkamp
Background: Cervical cancer remains a major global health challenge, with the highest incidence and mortality rates observed in sub-Saharan Africa. Despite progress in prevention and treatment, the management of advanced and recurrent disease remains difficult. Aim: This review explores the potential role of cannabinoids in cervical cancer therapy, with a focus on their integration into existing treatment strategies, combination therapies, and nanotechnology-based delivery systems. Methods: A critical synthesis of preclinical studies and emerging therapeutic approaches was conducted, examining the anticancer properties of cannabinoids, their mechanisms of action, and their application within combination and nanotechnology-based treatment modalities. Results: Cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) demonstrate anticancer effects by inducing apoptosis, inhibiting cell proliferation, and suppressing metastasis. Mechanistic studies highlight their ability to promote oxidative stress, modulate key signalling pathways, and influence immune responses in cervical cancer cells. Combination therapies involving cannabinoids with chemotherapy, radiotherapy, and immunotherapy show enhanced efficacy and reduced drug resistance. Furthermore, nanotechnology-based delivery systems offer advantages including targeted drug release, improved solubility, controlled dosing, and decreased systemic toxicity. Conclusion: Cannabinoids represent a promising adjunct in cervical cancer management. However, successful clinical translation requires optimisation of formulations, establishment of dosing protocols, and comprehensive safety evaluation. Future research should also explore biomarker-driven personalised medicine approaches. Standardisation, along with addressing regulatory and ethical challenges, will be crucial for the integration of cannabinoid-based therapies into mainstream cervical cancer treatment.

22 September 2020 in Molecules
Verified
Journal Article
Open access
PDF file
MLMaphuti Lebelo
Maphuti Lebelo
AJAnnie Joubert
Annie Joubert
MVMichelle Visagie
Michelle Visagie
2-Methoxyestradiol (2ME), a 17β-estradiol metabolite, exerts anticancer properties in vitro and in vivo. To address 2ME’s low bioavailability, research led to the in silico design of sulphamoylated 2ME analogues. However, the role of oxidative stress induced in the activity exerted by sulphamoylated compounds remains elusive. In the current study, the influence of 2-Ethyl-17-oxoestra-1,3,5(10)-trien-3-yl sulphamate (ESE-one) on reactive oxygen species (ROS) induction and its effect on cell proliferation, as well as morphology, were assessed in breast tumorigenic cells (MCF-7 and MDA-MB-231). Fluorescent microscopy showed that sulphamoylated estradiol analogues induced hydrogen peroxide and superoxide anion, correlating with decreased cell growth demonstrated by spectrophotometry data. ESE-one exposure resulted in antiproliferation which was repressed by tiron (superoxide inhibitor), trolox (peroxyl inhibitor) and N,N′-dimethylthiourea (DMTU) (hydrogen peroxide inhibitor). Morphological studies demonstrated that tiron, trolox and DMTU significantly decreased the number of rounded cells and shrunken cells in MCF-7 and MDA-MB-231 cells induced by ESE-one. This in vitro study suggests that ESE-one induces growth inhibition and cell rounding by production of superoxide anion, peroxyl radical and hydrogen peroxide. Identification of these biological changes in cancer cells caused by sulphamoylated compounds hugely contributes towards improvement of anticancer strategies and the ROS-dependent cell death pathways in tumorigenic breast cells.

29 April 2026 in Cancer Reports
Verified
Journal Article
Open access
SMS. P. Mathibela
S. P. Mathibela
MLMaphuti Lebelo
Maphuti Lebelo
Vanessa SteenkampVanessa Steenkamp
Vanessa Steenkamp
Introduction: Cervical cancer remains a leading cause of cancer‐related mortality among women globally, particularly in low‐ and middle‐income countries. Cisplatin, a standard chemotherapeutic agent, is limited by severe toxicities and chemoresistance. This study aimed to assess the effects of cisplatin in combination with phytocannabinoids, Δ9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) on cell proliferation, morphology, cell cycle progression, cell death, and DNA damage. Methods: Synergistic interactions between THC, CBD, and cisplatin were assessed in HeLa, SiHa, and MCF‐12A cells using the checkerboard assay and SRB assay. Cell morphology, cell cycle progression, apoptosis induction, autophagic activity, and DNA repair gene expression were evaluated using various techniques. Results: The THC–CBD–cisplatin combination exhibited the strongest apoptotic response in cancer cells (HeLa 53%, SiHa 58%), while minimally affecting MCF‐12A cells (32%). Cannabinoid co‐treatment amplified the antiproliferative and pro‐apoptotic effects of cisplatin in HeLa and SiHa cells. The triple combination induced a G2/M arrest in HeLa cells and sub‐G1 accumulation in SiHa cells. Autophagic activity, indicated by LC3B puncta formation, increased in HeLa and SiHa cells following THC and CBD exposure. DNA repair genes XRCC1 and RAD51 were downregulated by the cannabinoid–cisplatin combination. Conclusion: These findings demonstrate that combining THC and CBD with cisplatin results in enhanced and mechanistically diverse anticancer effects, with a higher degree of selectivity for cervical cancer cells compared to non‐cancerous MCF‐12A cells by inducing apoptosis and autophagy while inhibiting DNA repair capacity. This study highlights the potential of cannabinoid‐based combination therapies as a promising approach for cervical cancer treatment.

25 January 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MLMaphuti Lebelo
Maphuti Lebelo
AJAnnie Joubert
Annie Joubert
MVMichelle Visagie
Michelle Visagie
Recent findings revealed that 2-ethyl-17-oxoestra-1,3,5(10)-trien-3-yl sulfamate (ESE-one) induces antiproliferative activity and cell rounding dependent on the generation of superoxide anion, hydrogen peroxide and peroxyl radical. In the current study, the role of these reactive oxygen species was assessed in the activity exerted by ESE-one on cell cycle progression, mitochondrial membrane potential and cell death induction in breast tumorigenic cells. The influence of ESE-one was also investigated on superoxide dismutase and catalase activity. ESE-one induced a time-dependent accumulation of cells in the G1 phase and G2/M phase that is partially impaired by tiron and trolox and N,N′-dimethylthiourea suggesting that superoxide anion, hydrogen peroxide and peroxyl radical are required for these effects exerted by ESE-one. Flow cytometry data in MCF-7 cells demonstrated that tiron decreased depolarization of the membrane potential in ESE-one exposed cells, indicating that superoxide anion plays a role in the depolarization effects induced by ESE-one. Spectrophotometry data showed that ESE-one decreased catalase activity in both cell lines. This study contributes towards pertinent information regarding the effects of an in silico-designed sulfamoylated compound on antioxidant enzymes leading to aberrant quantities of specific reactive oxygen species resulting in antimitotic activity culminating in the induction of cell death in breast cancer cell lines.

11 March 2026 in Cancer Reports
Verified
Journal Article
Open access
SMSanele Priscillia Mathibela
Sanele Priscillia Mathibela
MLMaphuti Lebelo
Maphuti Lebelo
Vanessa SteenkampVanessa Steenkamp
Vanessa Steenkamp
Background: Fetal calf serum (FCS) is a key supplement in cell culture, providing nutrients, and growth factors that support cancer cell proliferation. Studies suggest that compound cytotoxicity profiles in vitro vary depending on FCS concentration in culture medium. The study aimed to examine how extracellular conditions influence the in vitro response of cancer cells to phytocannabinoids, with particular emphasis on serum supplementation. Methods and Results: Cells were exposed to CBD and THC in media containing 0.5% or 10% FCS for 24–72 h. Cell viability was assessed using the sulforhodamine B assay and live‐cell imaging. Significantly enhanced cytotoxic effects of CBD and THC were noted under low‐serum conditions (0.5% FCS) compared to standard conditions (10% FCS), particularly after 72 h incubation. THC demonstrated greater cytotoxicity than CBD in SiHa cells, while both compounds showed similar effects in HeLa cells. Conclusion: The study demonstrates that serum concentration critically modulates the cytotoxic potency of cannabinoids. Reduced FCS enhances cannabinoid efficacy by limiting protein binding, emphasizing the need to optimize serum conditions for accurate in vitro cytotoxicity assessments.